Sandbox:Roukoz: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin Examination
|-
|-
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
|-  
|-  
Line 18: Line 18:
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Risk factors
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Areas affected
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Areas affected
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Unique features
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Unique features
!Dermoscopy Features
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous squamous cell carcinoma'''<ref name="pmid9610717">{{cite journal| author=English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL| title=Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. | journal=Int J Cancer | year= 1998 | volume= 76 | issue= 5 | pages= 628-34 | pmid=9610717 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9610717  }} </ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous squamous cell carcinoma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* SCC in situ
* SCC in situ
Line 36: Line 37:
* In fair-skinned individuals, SCCs most commonly arise in sites frequently exposed to the sun
* In fair-skinned individuals, SCCs most commonly arise in sites frequently exposed to the sun


* In black individuals, common sites for SCC include the legs, anus, and areas of chronic inflammation or scarring<ref name="pmid17052479">{{cite journal| author=Gloster HM, Neal K| title=Skin cancer in skin of color. | journal=J Am Acad Dermatol | year= 2006 | volume= 55 | issue= 5 | pages= 741-60; quiz 761-4 | pmid=17052479 | doi=10.1016/j.jaad.2005.08.063 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17052479  }} </ref>
* In black individuals, common sites for SCC include the legs, anus, and areas of chronic inflammation or scarring
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Keratinocytic dysplasia involving the full thickness of the epidermis without infiltration of atypical cells into the dermis
* Keratinocytic dysplasia involving the full thickness of the epidermis without infiltration of atypical cells into the dermis
Line 46: Line 48:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Lesions of invasive SCC are often asymptomatic but may be painful or pruritic.
| style="background: #F5F5F5; padding: 5px;" |Lesions of invasive SCC are often asymptomatic but may be painful or pruritic.
| style="background: #F5F5F5; padding: 5px;" |Local neurologic symptoms (eg, numbness, stinging, burning, paresthesias, paralysis, or visual changes) occur in approximately one-third of patients with histologic perineural invasion by the tumor<ref name="pmid19681994">{{cite journal| author=Reule RB, Golda NJ, Wheeland RG| title=Treatment of cutaneous squamous cell carcinoma with perineural invasion using Mohs micrographic surgery: report of two cases and review of the literature. | journal=Dermatol Surg | year= 2009 | volume= 35 | issue= 10 | pages= 1559-66 | pmid=19681994 | doi=10.1111/j.1524-4725.2009.01276.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19681994  }} </ref>
| style="background: #F5F5F5; padding: 5px;" |Local neurologic symptoms (eg, numbness, stinging, burning, paresthesias, paralysis, or visual changes) occur in approximately one-third of patients with histologic perineural invasion by the tumor
| style="background: #F5F5F5; padding: 5px;" |Well-differentiated lesions usually appear as indurated or firm, hyperkeratotic papules, plaques, or nodules  
| style="background: #F5F5F5; padding: 5px;" |Well-differentiated lesions usually appear as indurated or firm, hyperkeratotic papules, plaques, or nodules  
| style="background: #F5F5F5; padding: 5px;" |Poorly differentiated lesions are usually fleshy, soft, granulomatous papules or nodules that lack the hyperkeratosis that is often seen in well-differentiated lesions
| style="background: #F5F5F5; padding: 5px;" |Poorly differentiated lesions are usually fleshy, soft, granulomatous papules or nodules that lack the hyperkeratosis that is often seen in well-differentiated lesions
Line 53: Line 55:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma'''<ref name="pmid26853179">{{cite journal| author=Kwiek B, Schwartz RA| title=Keratoacanthoma (KA): An update and review. | journal=J Am Acad Dermatol | year= 2016 | volume= 74 | issue= 6 | pages= 1220-33 | pmid=26853179 | doi=10.1016/j.jaad.2015.11.033 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26853179  }} </ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma'''
| style="background: #F5F5F5; padding: 5px;" |keratocytic epithelial tumors
| style="background: #F5F5F5; padding: 5px;" |keratocytic epithelial tumors
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Initial lesion: small pink macule
Later: papular quality and eventually forms a circumscribed nodule.
| style="background: #F5F5F5; padding: 5px;" |The periphery of the nodule tends to be skin-colored or mildly erythematous and may have accompanying telangiectasias
| style="background: #F5F5F5; padding: 5px;" |The center of the nodule typically demonstrates a prominent keratinous core.
| style="background: #F5F5F5; padding: 5px;" |
* Skin color
* Ultraviolet radiation
* Genetics
* Drug exposure (BRAF inhibitors)
* Trauma (surgery, laser therapy, cryotherapy or accidental trauma)
* Chemical carcinogens (tar, pitch, polyaromatic hydrocarbons)
* Human papillomavirus infection
| style="background: #F5F5F5; padding: 5px;" |
* Develops on sun-exposed areas of the skin.<ref name="pmid10949454">{{cite journal| author=Sánchez Yus E, Simón P, Requena L, Ambrojo P, de Eusebio E| title=Solitary keratoacanthoma: a self-healing proliferation that frequently becomes malignant. | journal=Am J Dermatopathol | year= 2000 | volume= 22 | issue= 4 | pages= 305-10 | pmid=10949454 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10949454  }}</ref>
* The face (especially the eyelids, nose, cheek, and lower lip), neck, hands, and arms are common sites for involvement<ref name="pmid205416762">{{cite journal| author=Ko CJ| title=Keratoacanthoma: facts and controversies. | journal=Clin Dermatol | year= 2010 | volume= 28 | issue= 3 | pages= 254-61 | pmid=20541676 | doi=10.1016/j.clindermatol.2009.06.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20541676  }}</ref>
| style="background: #F5F5F5; padding: 5px;" |a history of rapid growth within weeks favors this diagnosis
|
| style="background: #F5F5F5; padding: 5px;" |Keratoacanthomas are keratocytic epithelial tumors that clinically and histologically resemble SCC
| style="background: #F5F5F5; padding: 5px;" |
* It is controversial whether keratoacanthomas represent a subtype of well-differentiated SCC or a separate entity
* Dermoscopy may aid in clinically distinguishing KA from other lesions but cannot reliably distinguish KA from squamous cell carcinoma
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Muir-Torre
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Keratoacanthomas are usually found on actinically damaged skin.
| style="background: #F5F5F5; padding: 5px;" |Lesions typically exhibit rapid initial growth
| style="background: #F5F5F5; padding: 5px;" |dome-shaped or crateriform nodules with a central keratotic core
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |It is controversial whether keratoacanthomas represent a subtype of well-differentiated SCC or a separate entity
| style="background: #F5F5F5; padding: 5px;" |incidental detection of multiple lesions suspicious for sebaceous tumors during the skin examination may suggest the possibility of the Muir-Torre variant of Lynch syndrome
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Merkel cell carcinoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Merkel cell carcinoma'''
Line 79: Line 111:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule
| style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule
Line 92: Line 125:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |Cells proliferate downwards through the skin (vertical growth)
| style="background: #F5F5F5; padding: 5px;" |Cells proliferate downwards through the skin (vertical growth)
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 107: Line 141:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 122: Line 157:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 135: Line 171:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* large, hyperchromatic, oval nuclei and little cytoplasm
* large, hyperchromatic, oval nuclei and little cytoplasm
Line 150: Line 187:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 163: Line 201:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes;
| style="background: #F5F5F5; padding: 5px;" |The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes;
Line 176: Line 215:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 189: Line 229:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Suspected due to evidence of eyelash loss
| style="background: #F5F5F5; padding: 5px;" |Suspected due to evidence of eyelash loss
Line 202: Line 243:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Develops in skeletal muscles usually
| style="background: #F5F5F5; padding: 5px;" |Develops in skeletal muscles usually
Line 215: Line 257:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 228: Line 271:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 241: Line 285:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |Similar to mammary paget disease
| style="background: #F5F5F5; padding: 5px;" |Similar to mammary paget disease
| style="background: #F5F5F5; padding: 5px;" |chronic
| style="background: #F5F5F5; padding: 5px;" |chronic
Line 254: Line 299:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 267: Line 313:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Caused by HPV
| style="background: #F5F5F5; padding: 5px;" |Caused by HPV
Line 280: Line 327:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 293: Line 341:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 309: Line 358:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Chronic condition
| style="background: #F5F5F5; padding: 5px;" |Chronic condition
Line 322: Line 372:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Chronic condition
| style="background: #F5F5F5; padding: 5px;" |Chronic condition
Line 335: Line 386:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 348: Line 400:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 361: Line 414:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 375: Line 429:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 388: Line 443:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Not contagious
| style="background: #F5F5F5; padding: 5px;" |Not contagious
Line 401: Line 457:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Chronic and sometimes accompanied by asthma
| style="background: #F5F5F5; padding: 5px;" |Chronic and sometimes accompanied by asthma
Line 414: Line 471:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 427: Line 485:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 440: Line 499:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 453: Line 513:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |Contains choristomatous tissue  
| style="background: #F5F5F5; padding: 5px;" |Contains choristomatous tissue  
| style="background: #F5F5F5; padding: 5px;" |Benign congenital tumor
| style="background: #F5F5F5; padding: 5px;" |Benign congenital tumor
Line 467: Line 528:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Rare autosomal-dominant disorder of the conjunctiva and oral mucosa
| style="background: #F5F5F5; padding: 5px;" |Rare autosomal-dominant disorder of the conjunctiva and oral mucosa
Line 480: Line 542:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 493: Line 556:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |Containing fibromatous elements
| style="background: #F5F5F5; padding: 5px;" |Containing fibromatous elements
| style="background: #F5F5F5; padding: 5px;" |Arises due to disturbed systemic lipid metabolism
| style="background: #F5F5F5; padding: 5px;" |Arises due to disturbed systemic lipid metabolism
Line 507: Line 571:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 520: Line 585:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Typically  
| style="background: #F5F5F5; padding: 5px;" |Typically  
Line 533: Line 599:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 546: Line 613:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 559: Line 627:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Very rare
| style="background: #F5F5F5; padding: 5px;" |Very rare
Line 572: Line 641:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Keratosis follicularis
| style="background: #F5F5F5; padding: 5px;" |Keratosis follicularis
Line 585: Line 655:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Mycosis fungoides
| style="background: #F5F5F5; padding: 5px;" |Mycosis fungoides
Line 598: Line 669:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 613: Line 685:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Verrucous carcinoma on the plantar foot
| style="background: #F5F5F5; padding: 5px;" |Verrucous carcinoma on the plantar foot
Line 626: Line 699:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |also known as giant condyloma acuminatum of Buschke-Loewenstein
| style="background: #F5F5F5; padding: 5px;" |also known as giant condyloma acuminatum of Buschke-Loewenstein
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Found on actinically damaged skin
| style="background: #F5F5F5; padding: 5px;" |Rapid initial growth
| style="background: #F5F5F5; padding: 5px;" |Dome-shaped or crateriform nodules with a central keratotic core
| style="background: #F5F5F5; padding: 5px;" |Increased size
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |keratocytic epithelial tumors
|}
|}
SCC in situ: Frequently, there is associated thickening of the epidermis (acanthosis), as well as hyperkeratosis and parakeratosis of the stratum corneum. In contrast to SCC in situ, actinic keratoses demonstrate only partial-thickness epidermal dysplasia.
SCC in situ: Frequently, there is associated thickening of the epidermis (acanthosis), as well as hyperkeratosis and parakeratosis of the stratum corneum. In contrast to SCC in situ, actinic keratoses demonstrate only partial-thickness epidermal dysplasia.
<references />
<references />

Revision as of 00:32, 18 February 2019

Diseases Clinical manifestations Para-clinical findings Additional findings
Symptoms Skin Examination
Lab Findings Histopathology
Names Symptom 2 Symptom 3 Physical exam 1 Physical exam 2 Physical exam 3 Risk factors Areas affected Unique features Dermoscopy Features
Cutaneous squamous cell carcinoma
  • SCC in situ
  • Bowen's disease
usually asymptomatic well-demarcated, scaly patch or plaque hyperkeratotic, or ulcerative lesions Lesions are often erythematous but can also be skin colored or pigmented. Any cutaneous surface, including the head, neck, trunk, extremities, oral mucosa, shoulders, chest and back
  • In fair-skinned individuals, SCCs most commonly arise in sites frequently exposed to the sun
  • In black individuals, common sites for SCC include the legs, anus, and areas of chronic inflammation or scarring
  • Keratinocytic dysplasia involving the full thickness of the epidermis without infiltration of atypical cells into the dermis
  • The keratinocytes are pleomorphic with hyperchromatic nuclei, and numerous mitoses are present.
SCC in situ lesions tend to grow slowly, enlarging over the course of years
Invasive squamous cell carcinoma Lesions of invasive SCC are often asymptomatic but may be painful or pruritic. Local neurologic symptoms (eg, numbness, stinging, burning, paresthesias, paralysis, or visual changes) occur in approximately one-third of patients with histologic perineural invasion by the tumor Well-differentiated lesions usually appear as indurated or firm, hyperkeratotic papules, plaques, or nodules Poorly differentiated lesions are usually fleshy, soft, granulomatous papules or nodules that lack the hyperkeratosis that is often seen in well-differentiated lesions Poorly differentiated tumors may have ulceration, hemorrhage, or areas of necrosis.
Keratoacanthoma keratocytic epithelial tumors Initial lesion: small pink macule

Later: papular quality and eventually forms a circumscribed nodule.

The periphery of the nodule tends to be skin-colored or mildly erythematous and may have accompanying telangiectasias The center of the nodule typically demonstrates a prominent keratinous core.
  • Skin color
  • Ultraviolet radiation
  • Genetics
  • Drug exposure (BRAF inhibitors)
  • Trauma (surgery, laser therapy, cryotherapy or accidental trauma)
  • Chemical carcinogens (tar, pitch, polyaromatic hydrocarbons)
  • Human papillomavirus infection
  • Develops on sun-exposed areas of the skin.[1]
  • The face (especially the eyelids, nose, cheek, and lower lip), neck, hands, and arms are common sites for involvement[2]
a history of rapid growth within weeks favors this diagnosis Keratoacanthomas are keratocytic epithelial tumors that clinically and histologically resemble SCC
  • It is controversial whether keratoacanthomas represent a subtype of well-differentiated SCC or a separate entity
  • Dermoscopy may aid in clinically distinguishing KA from other lesions but cannot reliably distinguish KA from squamous cell carcinoma
Muir-Torre incidental detection of multiple lesions suspicious for sebaceous tumors during the skin examination may suggest the possibility of the Muir-Torre variant of Lynch syndrome
Merkel cell carcinoma Starts on areas of skin exposed to the sun Single pink, red, or purple shiny bump Painless Blue-red, dome-shaped nodule
Nodular malignant melanoma Lump that has been rapidly growing over the past weeks Cells proliferate downwards through the skin (vertical growth)
  • Two-thirds arise in normal skin, the rest in existing moles
  • Genetic component in some cases with a positive family history
Amelanotic melanoma Color usually pink, purple or normal skin color Usually have an asymmetrical shape with an irregular border Red, nonspecific lesion with slightly elevated borders
  • Do not make melanin, so lesions are not pigmented
Basal cell carcinoma Coarse scale lesion
Superficial basal cell carcinoma Scaly patch Erythematous lesion
  • large, hyperchromatic, oval nuclei and little cytoplasm
  • well differentiated and cells appear histologically similar to basal cells of the epidermis
Nodular basal cell carcinoma Pearly papule with telangiectasias
Cutaneous metastases of internal malignancy Other sites lungs, liver, brain, skin, or bone. The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes;
Benign Skin Lesions
Sebaceous cell carcinoma Yellow-nodule Suspected due to evidence of eyelash loss
Rhabdomyosarcoma Bulging of the eye or a swollen eyelid Develops in skeletal muscles usually
Actinic keratoses Pain Hyperkeratosis Erythema less pigmentation, and tend to be somewhat smaller in size.
Prurigo nodules Hard lesion Itchy lumps
Paget disease Eczema-like rash of the skin Around the genital regions of males and females. Similar to mammary paget disease chronic
Inflamed seborrheic keratosis Waxy, "stuck on," often hyperkeratotic appearance
Viral warts Verrucous lesion Caused by HPV
Pyogenic granuloma Rapidly growing Red, dome-shaped Friable papule with a collarette of scale
Bowenoid papulosis multiple, red- to brown-colored, small papules that
  • primarily arise on genitals
  • induced by human papillomavirus (HPV) infection
Nummular eczema Itchy lesions Coin shaped spots Chronic condition
Psoriasis Flaking, inflammation Thick, white, silvery, or red patches of skin Chronic condition
Pyoderma gangrenosum Purulent ulcer Ragged and violaceous border
Venous stasis ulcers
Traumatic ulcers
Sebaceous Hyperplasia Lesions can be single or multiple lesions

Yellowish, soft, small papules on the face

Usually on the nose, cheeks, and forehead
Allergic Contact Dermatitis Itchy rash Red rash Not contagious
Atopic Dermatitis Itchy rash Fever Red rash Chronic and sometimes accompanied by asthma
Atypical Fibroxanthoma Erythematous, dome-shaped papule
Nevus
Chemical Burns
Limbal Dermoid Contains choristomatous tissue Benign congenital tumor
Benign hereditary intraepithelial dyskeratosis Rare autosomal-dominant disorder of the conjunctiva and oral mucosa
primary acquired melanosis
Fibrous xanthoma Containing fibromatous elements Arises due to disturbed systemic lipid metabolism
Inflamed seborrheic keratosis Inflamed and hyperpigmented On dermatoscopic evaluation, presence of horned cysts and hairpin-shaped blood vessels
Juvenile xanthogranuloma Reddened, yellowish-tan color of lesions Slightly raised bumps Typically
Cutaneous fungal infections
Desmoplastic trichoepithelioma
Adnexal carcinoma Very rare
Darier disease Keratosis follicularis
Cutaneous T-cell lymphoma Mycosis fungoides
Marjolin's ulcer Lesions in sites of chronic wounds and scars Excessive granulation tissue, Rolled or everted wound margins Bleeding on touch
  • rare type of SCC
  • Very slow malignant transformation
Epithelioma cuniculatum Increased size Verrucous carcinoma on the plantar foot
Anogenital also known as giant condyloma acuminatum of Buschke-Loewenstein

SCC in situ: Frequently, there is associated thickening of the epidermis (acanthosis), as well as hyperkeratosis and parakeratosis of the stratum corneum. In contrast to SCC in situ, actinic keratoses demonstrate only partial-thickness epidermal dysplasia.

  1. Sánchez Yus E, Simón P, Requena L, Ambrojo P, de Eusebio E (2000). "Solitary keratoacanthoma: a self-healing proliferation that frequently becomes malignant". Am J Dermatopathol. 22 (4): 305–10. PMID 10949454.
  2. Ko CJ (2010). "Keratoacanthoma: facts and controversies". Clin Dermatol. 28 (3): 254–61. doi:10.1016/j.clindermatol.2009.06.010. PMID 20541676.